Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies

Vaccine

Volumn 31, Issue 39, 2013, Pages 4235-4240

  Volz, Asisa ^a   Sutter, Gerd ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Poxviruses; Preclinical studies; Recombinant MVA vaccines; Vaccine efficacy

Indexed keywords

ORTHOPOXVIRUS VACCINE; SMALLPOX VACCINE; VALACICLOVIR;

ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; BIOSAFETY; CHIKUNGUNYA ALPHAVIRUS; COWPOX VIRUS; DRUG EFFICACY; ECTROMELIA VIRUS; FOLLOW UP; HUMORAL IMMUNITY; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N8; INFLUENZA VIRUS A H5N1; MODIFIED VACCINIA VIRUS ANKARA; MONKEYPOX VIRUS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINATION; VACCINIA VIRUS; VIRUS REPLICATION; WEST NILE FLAVIVIRUS;

POXVIRUSES; PRECLINICAL STUDIES; RECOMBINANT MVA VACCINES; VACCINE EFFICACY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; GENETIC ENGINEERING; HUMANS; MALARIA; SMALLPOX; TUBERCULOSIS; VACCINATION; VACCINES, ATTENUATED; VACCINIA VIRUS; VARIOLA VIRUS; VIRAL VACCINES;

EID: 84882835373     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.03.016     Document Type: Article

References (68)

1. Baylor M. EMA/CHMP/VWP/141697/2009 guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines. Pediatrics 2011, 127:S23-S30.
2. Mayr A., Munz E. Veränderung von Vaccinevirus durch Dauerpassagen in Hühnerembryofibroblastenkulturen. Zentralbl Bakteriol B 1964, I(195):24-35.
3. Mayr A., Stickl H., Müller H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentralbl Bakteriol B 1978, 167(5-6):375-390. [author's transl.].
4. Stickl H., Hochstein-Mintzel V., Mayr A. MVA-Stufenimpfung gegen Pocken. Dtsch Med Wochenschr 1974, 99(47):2386-2392.
5. Antoine G., Scheiflinger F., Dorner F., Falkner F.G. The complete genomic sequence of the Modified Vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998, 244(2):365-396.
6. Meyer H., Sutter G., Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 1991, 72(May (5)):1031-1038.
7. Ramírez J.C., Gherardi M.M., Esteban M. Biology of attenuated Modified Vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the western reserve strain and advantages as a vaccine. J Virol 2000, 74(January (2)):923-933.
8. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci 1992, 89(November (22)):10847-10851.
9. Stittelaar K.J., Wyatt L.S., de Swart R.L., Vos H.W., Groen J., van Amerongen G., et al. Protective immunity in macaques vaccinated with a Modified Vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J Virol 2000, 74(May (9)):4236-4243.
10. Wyatt L.S., Earl P.L., Eller L.A., Moss B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A 2004, 101(March (13)):4590-4595.
11. O'Rourke A.M., Mescher M.F. Cytotoxic T-lymphocyte activation involves a cascade of signalling and adhesion events. Nature 1992, 358(6383):253-255.
12. Gasteiger G., Kastenmuller W., Ljapoci R., Sutter G., Drexler I. Cross-priming of cytotoxic T cells dictates antigen requisites for Modified Vaccinia virus Ankara vector vaccines. J Virol 2007, 81(November (21)):11925-11936.
13. Gorse G.J., Newman M.J., deCamp A., Hay C.M., De Rosa S.C., Noonan E., et al. DNA and Modified Vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults. Clin Vaccine Immunol 2012, 19(May (5)):649-658.
14. Schliehe C., Bitzer A., van den Broek M., Groettrup M. Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo. J Virol 2012, 86(September (18)):9782-9793.
15. Hirsch V.M., Fuerst T.R., Sutter G., Carroll M.W., Yang L.C., Goldstein S., et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in Modified Vaccinia virus Ankara. J Virol 1996, 70(June (6)):3741-3752.
16. Sutter G., Wyatt L.S., Foley P.L., Bennink J.R., Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994, 12(11):1032-1040.
17. Delaloye J., Roger T., Steiner-Tardivel Q-G., Le Roy D., Knaup Reymond M., Akira S., et al. Innate immune sensing of Modified Vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 2009, 5(6):e1000480.
18. Halle S., Dujardin H.C., Bakocevic N., Fleige H., Danzer H., Willenzon S., et al. Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. J Exp Med 2009, 206(November (12)):2593-2601.
19. Lehmann M.H., Kastenmuller W., Kandemir J.D., Brandt F., Suezer Y., Sutter G. Modified Vaccinia virus Ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. J Virol 2009, 83(March (6)):2540-2552.
20. Waibler Z., Anzaghe M., Ludwig H., Akira S., Weiss S., Sutter G., et al. Modified Vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses. J Virol 2007, 81(November (22)):12102-12110.
21. Kremer M., Volz A., Kreijtz J.H.C.M. Easy and efficient protocols for working with recombinant vaccinia virus MVA. Vaccinia Virus Poxvirol Methods Protoc 2012, 59-93.
22. Gómez C.E., Nájera J.L., Perdiguero B., García-Arriaza J., Sorzano C.O.S., Jiménez V., et al. The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. J Virol 2011, 85(November (21)):11468-11478.
23. ®: Modified Vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 2008, 8(1):13-24.
24. Bender B.S., Rowe C.A., Taylor S.F., Wyatt L.S., Moss B., Small P.A. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol 1996, 70(September (9)):6418-6424.
25. Rimmelzwaan G.F., Bodewes R., Osterhaus A.D.M.E. Vaccination strategies to protect children against seasonal and pandemic influenza. Vaccine 2011, 29(43):7551-7553.
26. Rimmelzwaan G.F., Sutter G. Candidate influenza vaccines based on recombinant Modified Vaccinia virus Ankara. Expert Rev Vaccines 2009, 8(4):447-454.
27. Breathnach C.C., Clark H.J., Clark R.C., Olsen C.W., Townsend H.G.G., Lunn D.P. Immunization with recombinant Modified Vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge. Vaccine 2006, 24(8):1180-1190.
28. Breathnach C.C., Rudersdorf R., Lunn D.P. Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination. Vet Immunol Immunopathol 2004, 98(3-4):127-136.
29. Kreijtz J.H.C.M., Suezer Y., de Mutsert G., van den Brand J.M.A., van Amerongen G., Schnierle B.S., et al. Recombinant Modified Vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis 2009, 199(February (3)):405-413.
30. Hessel A., Schwendinger M., Fritz D., Coulibaly S., Holzer G.W., Sabarth N., et al. A pandemic influenza H1N1 live vaccine based on Modified Vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations. PLoS ONE 2010, 5(8):e12217.
31. Kreijtz J.H.C.M., Süzer Y., Bodewes R., Schwantes A., van Amerongen G., Verburgh R.J., et al. Evaluation of a Modified Vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model. J Gen Virol 2010, 91(November (11)):2745-2752.
32. Ernst J.D. The immunological life cycle of tuberculosis. Nat Rev Immunol 2012, 12(8):581-591.
33. Sauerwein R.W., Roestenberg M., Moorthy V.S. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 2011, 11(1):57-64.
34. Reynell L., Trkola A. HIV vaccines: an attainable goal?. Swiss Med Wkly 2012, 2(March (142)):w13535. 10.4414/smw.2012.
35. Hill A.V.S., Reyes-Sandoval A., O'Hara G., Ewer K., Lawrie A., Goodman A., et al. Prime-boost vectored malaria vaccines: progress and prospects. Human Vaccines 2010, 6(1):78-83.
36. García F., Bernaldo de Quirós J.C.L., Gómez C.E., Perdiguero B., Nájera J.L., Jiménez V., et al. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: a phase I clinical trial (RISVAC02). Vaccine 2011, 29(46):8309-8316.
37. Goepfert P.A., Elizaga M.L., Sato A., Qin L., Cardinali M., Hay C.M., et al. Phase 1 safety and immunogenicity testing of DNA and recombinant Modified Vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011, 203(March (5)):610-619.
38. Sandström E., Nilsson C., Hejdeman B., Bråve A., Bratt G., Robb M., et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant Modified Vaccinia virus Ankara. J Infect Dis 2008, 198(November (10)):1482-1490.
39. Brandler S., Lepelley A., Desdouits M., Guivel-Benhassine F., Ceccaldi P-E., Lévy Y., et al. Preclinical studies of a Modified Vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect. J Virol 2010, 84(May (10)):5314-5328.
40. Gómez C.E., Perdiguero B., Jiménez V., Filali-Mouhim A., Ghneim K., Haddad E.K., et al. Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. PLoS ONE 2012, 7(4):e35485.
41. Van Rompay K. The use of nonhuman primate models of HIV infection for the evaluation of antiviral strategies. AIDS Res Hum Retroviruses 2012, 28(January (1)):16-35.
42. Horton H., Vogel T.U., Carter D.K., Vielhuber K., Fuller D.H., Shipley T., et al. Immunization of rhesus macaques with a DNA prime/Modified Vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J Virol 2002, 76(July (14)):7187-7202.
43. Nilsson C., Sutter G., Walther-Jallow L., ten Haaft P., Åkerblom L., Heeney J., et al. Immunization with recombinant Modified Vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques. J Gen Virol 2002, 83(April (4)):807-818.
44. Kannanganat S., Nigam P., Velu V., Earl P.L., Lai L., Chennareddi L., et al. Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine. J Immunol 2010, 185(December (12)):7262-7273.
45. Shimada M., Wang H.B., Kondo A., Xu X.P., Yoshida A., Shinoda K., et al. Effect of therapeutic immunization using Ad5/35 and MVA vectors on SIV infection of rhesus monkeys undergoing antiretroviral therapy. Gene Ther 2008, 16(2):218-228.
46. Wang H.B., Kondo A., Yoshida A., Yoshizaki S., Abe S., Bao L.L., et al. Partial protection against SIV challenge by vaccination of adenovirus and MVA vectors in rhesus monkeys. Gene Ther 2009, 17(1):4-13.
47. Keele B.F., Li H., Learn G.H., Hraber P., Giorgi E.E., Grayson T., et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009, 206(May (5)):1117-1134.
48. Lai L., Kwa S., Kozlowski P.A., Montefiori D.C., Ferrari G., Johnson W.E., et al. Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/Modified Vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis 2011, 204(July (1)):164-173.
49. Lai L., Kwa S-F., Kozlowski P.A., Montefiori D.C., Nolen T.L., Hudgens M.G., et al. SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine 2012, 30(9):1737-1745.
50. Moss B. Smallpox vaccines: targets of protective immunity. Immunol Rev 2011, 239(1):8-26.
51. Coulibaly S., Brühl P., Mayrhofer J., Schmid K., Gerencer M., Falkner F.G. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 2005, 341(1):91-101.
52. Drexler I., Staib C., Kastenmüller W., Stevanović S., Schmidt B., Lemonnier F.A., et al. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci 2003, 100(January (1)):217-222.
53. Earl P.L., Americo J.L., Wyatt L.S., Eller L.A., Whitbeck J.C., Cohen G.H., et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004, 428(6979):182-185.
54. Stittelaar K.J., van Amerongen G., Kondova I., Kuiken T., van Lavieren R.F., Pistoor F.H.M., et al. Modified Vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol 2005, 79(June (12)):7845-7851.
55. Edghill-Smith Y., Golding H., Manischewitz J., King L.R., Scott D., Bray M., et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 2005, 11(7):740-747.
56. Esteban D.J., Buller R.M.L. Ectromelia virus: the causative agent of mousepox. J Gen Virol 2005, 86(October (10)):2645-2659.
57. Fenner F. Mousepox (infectious ectromelia): past, present, and future. Lab Anim Sci 1981, 31(October):553-559.
58. Paran N., Suezer Y., Lustig S., Israely T., Schwantes A., Melamed S., et al. Postexposure immunization with Modified Vaccinia virus Ankara or conventional lister vaccine provides solid protection in a murine model of human smallpox. J Infect Dis 2009, 199(January (1)):39-48.
59. Samuelsson C., Hausmann J., Lauterbach H., Schmidt M., Akira S., Wagner H., et al. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest 2008, 118(5):1776-1784.
60. Staib C., Suezer Y., Kisling S., Kalinke U., Sutter G. Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with Modified Vaccinia virus Ankara. J Gen Virol 2006, 87(October (10)):2917-2921.
61. Kremer M., Suezer Y., Volz A., Frenz T., Majzoub M., Hanschmann K-M., et al. Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox. PLoS Pathog 2012, 8(3):e1002557.
62. Damon I.K., Davidson W.B., Hughes C.M., Olson V.A., Smith S.K., Holman R.C., et al. Evaluation of smallpox vaccines using variola neutralization. J Gen Virol 2009, 90(August (8)):1962-1966.
63. ® challenge. Vaccine 2007, 25(51):8562-8573.
64. Ferrier-Rembert A., Drillien R., Tournier J-N., Garin D., Crance J-M. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine. Vaccine 2008, 26(14):1794-1804.
65. Earl P.L., Americo J.L., Wyatt L.S., Espenshade O., Bassler J., Gong K., et al. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci 2008, 105(August (31)):10889-10894.
66. Kreijtz J.H.C.M., Suezer Y., van Amerongen G., de Mutsert G., Schnierle B.S., Wood J.M., et al. Recombinant Modified Vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis 2007, 195(June (11)):1598-1606.
67. Kreijtz J.H.C.M., Suezer Y., de Mutsert G., van Amerongen G., Schwantes A., van den Brand J.M.A., et al. MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. PLoS ONE 2009, 4(11):e7790.
68. Hessel A., Schwendinger M., Holzer G.W., Orlinger K.K., Coulibaly S., Savidis-Dacho H., et al. Vectors based on Modified Vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PLoS ONE 2011, 6(1):e16247.